Great Falls Clinic Open Research Studies
Learn more about Great Falls Clinic’s Clinical Research Department.
ATB200-02: Phase I/II
Treating: Pompe DiseaseCAIN457H2315: Phase III
Treating: Axial SpondyloarthritisIndication: Active non-radiographic Axial Spondyloarthritis
Status: Open and Currently Not Enrolling
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis
CAIN457K2340: Phase III
Treating: Axial SpondyloarthritisD169CC00001 (Deliver-HF): Phase III
Treating: Heart FailureStatus: Open/Currently enrolling
An international, double-blind, randomized, placebo-controlled phase III study to evaluate the effect of Dapagliflozin on reducing CV death or worsening heart failure in patient with heart failure with preserved ejection fraction (HFpEF)
EFC14828 (Amplitude-O): Phase III
Treating: DiabetesStatus: Open/Currently Not Enrolling
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of Efpeglenatide on cardiovascular outcomes in type 2 diabetes patients at high cardiovascular risk
IDR-OM-02: Phase III
Treating: Oral MucositisIndication: Squamous Cell Carcinoma (head/neck cancers)
Status: Open/Currently Enrolling
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
